Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06984497 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Sep 2025 to Feb 1, 2026 Show 6 more changesShow less
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary and study completion moved earlier from Dec 2027 to Dec 2026
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site contact updated
    • Publications: details revised at 2 of 2 entries
  2. Primary completion date: Dec 31, 2025 to Dec 2027v2 Show 5 more changesShow less
    • Start date: May 31, 2025 to Sep 2025
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: May 31, 2026 to Dec 2027
    • Site details revised
    • Publications: details revised at 2 of 2 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.
Trial Details
NCT Number NCT06984497
Lead Sponsor General Hospital of Shenyang Military Region
Conditions
(from sponsor)		 End-Stage Liver Diseases
Related terms Fibrosis
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov